Financial News 2008

ASTERAND PLC

("Asterand" or "the Company")

Change of Broker

April 24, 2008

Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical companies engaged in drug discovery research, is pleased to announce that with immediate effect it has appointed Daniel Stewart & Company plc as its Broker.

Martyn Coombs, Chief Executive Officer of Asterand, commented:

"Asterand is pleased to have Daniel Stewart on board as a partner. They have a breadth of experience and a successful track record in working with companies like Asterand. We look forward to their guidance in improving our visibility to shareholders and advancing the Company's market position."

Tom Jenkins, Director at Daniel Stewart & Company commented:

Daniel Stewart is excited to be appointed as broker to Asterand. We look forward to working with the Company on the next stage of its development as it seeks to further develop a leading position and market presence.

Enquiries:

Asterand plc
Martyn Coombs, Chief Executive Officer
Tel No: UK: + 44 (0) 1763 211 600
Tel No: US: + 001 (313) 2630960
www.asterand.com

Daniel Stewart & Company plc
Simon Leathers/Tom Jenkins
Tel No: UK: +44 (0) 20 7776 6550

Buchanan Communications
Lisa Baderoon/Rebecca Skye Dietrich
Tel No: UK: +44 (0) 20 7466 5000

Notes to Editors
Asterand is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the clinic.

Daniel Stewart Securities plc is an AIM-listed company providing a range of investment banking services to Small Cap publicly traded and non-publicly traded companies.

This information is provided by RNS

The company news service from the London Stock Exchange

END